Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;98(3):421-434.
doi: 10.1111/cbdd.13865. Epub 2021 Jul 3.

A consequence of drug targeting of aminoacyl-tRNA synthetases in Mycobacteriumtuberculosis

Umar Ndagi  1 , Hezekiel M Kumalo  2 , Ndumiso N Mhlongo  2
Affiliations
Review

A consequence of drug targeting of aminoacyl-tRNA synthetases in Mycobacteriumtuberculosis

Umar Ndagi et al. Chem Biol Drug Des. 2021 Sep.

Abstract

Drug-resistant Mycobacterium tuberculosis poses a great threat to public health and remains one of the red-flag tagged infectious diseases, with the tendency of comorbidity with other disease conditions such as HIV/AIDS. This perhaps is responsible for redoubling of effort in tuberculosis research and continuous change in patient management to optimize the drug therapy. Aminoacyl-tRNA synthetases are essential enzymes in M. tuberculosis that catalyse the transfer of a particular amino acid to its corresponding specific tRNA to form an aminoacyl-tRNA. These enzymes are believed to be novel antibacterial, antifungal and antiparasitic drug targets because of their role in the process of protein translation. Therefore, their existence as a compliment of M. tuberculosis has attracted a lot of research interest with the aim of curbing the scourge and provide the most effective drug in the treatment of tuberculosis. This leads to the discovery of a pool of aminoacyl-tRNA synthetases with their essential inhibitors. This review seeks to articulate the current advances in the development of new TB drugs exhibiting novelty in their mode of action with specific emphasis on aminoacyl-tRNA synthetases as drug targets.

Keywords: Mycobacterium tuberculosis; aminoacyl-tRNA synthetase; drug-resistance and drug target.

PubMed Disclaimer

References

REFERENCES

    1. Adachi, R., Okada, K., Skene, R., Ogawa, K., Miwa, M., Tsuchinaga, K., Ohkubo, S., Henta, T., & Kawamoto, T. (2017). Discovery of a novel prolyl-tRNA synthetase inhibitor and elucidation of its binding mode to the ATP site in complex with L-proline. Biochemical and Biophysical Research Communications, 488, 393-399. https://doi.org/10.1016/j.bbrc.2017.05.064
    1. Agarwal, V., & Nair, S. K. (2012). Aminoacyl tRNA synthetases as targets for antibiotic development. Medchemcomm, 3, 887-898. https://doi.org/10.1039/c2md20032e
    1. Ambrogelly, A, Söll, D, Nureki, O, Yokoyama, S, & Ibba, M (2013). Class I Lysyl-tRNA synthetases. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience.
    1. Banerjee, R., Schecter, G. F., Flood, J., & Porco, T. C. (2008). Extensively drug-resistant tuberculosis: New strains, new challenges. Expert Review of Anti-infective Therapy, 6(5), 713-724. https://doi.org/10.1586/14787210.6.5.713
    1. Barros-Álvarez, X., Turley, S., Ranade, R. M., Gillespie, J. R., Duster, N. A., Verlinde, C. L. M. J., Fan, E., Buckner, F. S., & Hol, W. G. J. (2018). The crystal structure of the drug target Mycobacterium tuberculosis methionyl-tRNA synthetase in complex with a catalytic intermediate. Acta Crystallographica Section F Structural Biology Communcations, 74, 245-254. https://doi.org/10.1107/S2053230X18003151

MeSH terms

LinkOut - more resources